Remote Monitored Systems said its Pharm2Farm subsidiary expects to produce a maximum of 1mln anti-viral face masks in January 2021 and 2mln in February.
The mask-making machine is now expected to be delivered on December 28 at the earliest, it added, with factory acceptance testing of the machine taking place today by manufacturer Lemu Group, to be followed by final finishing and hardening in the coming week.
Once delivery is taken by P2F’s Nottingham Biocity premises, it can begin building production towards a theoretical maximum capacity of 5mln masks per month if the machine is working 24-hours per day, seven days per week.
Pharm2farm uses a patented process for producing and functionalising nanoparticles for various applications including human, animal and crop health. Pharm2farm is a wholly owned subsidiary of Remote Monitored Systems (LON:RMS).